Document is current

Article History

Received: 29 August 2024

Accepted: 10 November 2024

First Online: 20 November 2024

Declarations

:

: This retrospective investigation and use of patient material and data was approved by the Ethics Committee of the University Hospital Frankfurt (SNO-9-2022).

: Not applicable.

: NGS was conducted and analyzed at Chronix Biomedical by JB, KBK and ES, who are employees of Chronix Biomedical an Oncocyte Company. JPS has received honoraria for lectures, advisory board participation, consulting, and travel grants from Abbvie, Roche, Boehringer, Bristol-Myers Squibb, Medac, Mundipharma, and UCB. PJW has received consulting fees and honoraria for lectures by Bayer, Sanofi, Janssen-Cilag, Novartis, Roche, MSD, Astellas Pharma, Bristol-Myers Squibb, Thermo Fisher Scientific, Molecular Health, Guardant Health, Sophia Genetics, Qiagen, Eli Lilly, Myriad, Hedera Dx, and Astra Zeneca and research support was provided by Astra Zeneca and Roche. HR received honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chop GmbH, Diaceutics, GlaxoSmithKline, HUeG, Janssen-Cilag, MCI, Merck, Novartis, Roche Pharma, Sanofi and Wolfsburg Klinikum and funding from Bristol-Myers Squibb. MWR has received a research grant from UCB. PSZ has received a lecture honorarium from Bristol-Myers Squibb. The remaining authors declare that the research was carried out without any commercial or financial relationships that could potentially create a conflict of interest.